WASHINGTON, DC, January 5, 2012 – The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine (RM) community, today released the agenda for its second annual State of the Industry Briefing and RM Insight Track. The meeting will take place on January 10 – 11, 2012 at the Park 55 Wyndham in San Francisco.
The Regenerative Medicine State of the Industry Briefing will focus on recent developments and the future outlook for regenerative medicine, cell therapy and other advanced therapeutics. A full day of panels focused on several disease areas will follow the briefing as part of the Regenerative Medicine Insight track at the Biotech Showcase 2012. The panels will be moderated by key analysts in the sector. Please see agenda below:
Tuesday, January 10, 2012
8:00 – 9:30 AM Regenerative Medicine State of the Industry Briefing
· Gil Van Bokkelen, CEO, Athersys (Moderator)
· Silviu Itescu, CEO, Mesoblast
· Tim Mayleben, CEO of Aaastrom
· Gary Rabin, CEO, Advanced Cell Technology
· Robin Smith, CEO, NeoStem
· Leanna Caron, VP & GM of Cell Therapy & Regenerative Medicine, Genzyme-Sanofi
· Ed Field, COO, Aldagen
· Jay Seigal, CBO, Johnson & Johnson
· Dean Tozer, Senior VP of Corporate Development, ABH-Shire
· Susan Solomon, CEO, New York Stem Cell Foundation
Therapeutic Focus Panels
9:30 – 10:45 AM Cardiovascular, AMI and PAD—Part 1
Analyst: Jason Butler, JMP Securities
· Amorcyte, Andrew Pecora, CSO
· Cytori, Marc Hendrick, President
· Athersys, Gil Van Bokkelen, CEO
· Mesoblast, Silviu Itescu, CEO
10:50AM – 12:15 PM Cardiovascular, CLI and Stroke—Part 2
Analyst: Ren Benjamin, Rodman and Renshaw
· Aastrom, Brian Gibson, VP Finance
· ReNeuron, Michael Hunt, CEO
· Aldagen, Ed Field, COO
· Tissue Genesis, Anton Krucky, CEO
· SanBio, Keita Mori, CEO
1:45 – 3:00 PM Neurodegenerative Disease, Ophthalmology and Spinal Injury
Analyst: Steve Brozak, WBB Securities
· StemCells, Inc., Martin McGlynn, CEO
· NeuralStem, Richard Garr, CEO
· InVivo, Frank Reynolds, Chairman of the Board, CEO, CFO,
· Advanced Cell Technology, Gary Rabin, CEO
3:00 – 4:15 PM Renal and AutoImmune Disease
Analyst: Kai Makay, Roth Capital
· Tengion, Mark Stejbach, VP, CCO
· Allocure, John Wirthlin, COO
· Tigenix, Eduardo Bravo, CEO
· Q Therapeutics, Deborah Eppstein, CEO
4:20 – 5:45 PM Tissue Engineering, Orthobiologics and Artificial Conduits to Wound Care and BioPrinting
Analyst: Jeffery Cohen, Ladenburg Thalmann & Co.
· ISTO, Scott Gill, CFO
· Organovo, Keith Murphy, CEO
· ABH – Shire, Dean Tozer, Senior VP of Corporate Development
· Healthpoint, Rob Bancroft, VP, Strategic and Corporate Development
· Axogen, Karen Zaderej, CEO
· Harvard Biosciences, David Green, CEO
Wednesday, January 11, 2012
9:00 – 10:30 AM Hematology & Immunology
Analyst: Stephen Dunn, LifeTech Capital
· Dendreon, David L. Urdal, Executive VP, CSO
· Prima BioMed, Martin Rogers, CEO
· ImmunoCellular, Manish Singh, CEO
· Coronado, Bobby Sandage, CEO
· bluebird bio, Jeffrey Walsh, COO
· NexImmune, Ken Carter, CEO
· Maxcyte, Doug Doerfler, CEO
To learn more and to register for the conference, please contact Rob Margolin at (646) 201-4192. Registration is complimentary for credentialed members of the media and the investment community. The State of the Industry briefing is open to the public, but attendance at the disease panels will require registration for individuals without press or investor credentials.
About Biotech Showcase™ (Innovation – Opportunity – Collaboration):
Now in its fourth year, Biotech Showcase™ will feature corporate presentations by 200+ innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of the annual JP Morgan Healthcare Conference, one of the most important healthcare industry events of the year which attracts thousands of healthcare and life science business executives to San Francisco. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group. Please visit their website for more information: www.biotechshowcase.com.
About The Alliance for Regenerative Medicine (ARM)
ARM is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM in September 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.
